Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07687589

The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals

This study investigates whether the gut hormone glucose-dependent insulinotropic polypeptide (GIP) can reduce feelings of nausea. GIP is naturally released after meals and is administered intravenously to healthy participants during the experiment. Nausea is induced using either glucagon-like peptide 1 (GLP-1), another gut hormone, or apomorphine, a medication known to trigger nausea. By combining these substances, the study aims to determine whether GIP can alleviate nausea. The findings may improve understanding of interactions between the gut and the brain.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Emesis Nausea Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive Vomiting

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Center for Clinical Metabolic Research, Herlev-Gentofte Hospital

Hellerup, 2900, Denmark

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or women, age of 18-60 years
  • BMI between 19-27 kg/m2 (both included)
  • informed consent

Exclusion criteria

  • Current or past treatment with GLP-1 or GIP/GLP-1 receptor-targeting compounds within the last six months
  • Gastrointestinal disorders that the investigator evaluates could interfere with induction of nausea (e.g. gastroparesis, functional dyspepsia and GI surgery)
  • Neurological disorders affecting nausea (e.g. severe migraines and neuropathy)
  • Any known eating disorders (e.g. anorexia nervosa and bulimia)
  • Pregnancy or breastfeeding
  • Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (> 2 times normal values) or present hepatobiliary disease
  • Kidney disease (estimated glomerular filtration rate (eGFR)<90 ml/min/1.73 m2) at screening
  • Severe arteriosclerotic heart disease or heart failure (NYHA class II-IV)
  • Glycated hemoglobin (HbA1c) ³ 48 mmol/mol and/or diagnosed type 1 or type 2 diabetes
  • Any condition that the investigator evaluates would interfere with study participation

Treatment and study plan

Glucose-dependent Insulinotropic Polypeptide (GIP)

Other

GIP - gut hormone

GLP-1 (7-36) amide

Other

gut hormone - GLP-1(7-36)NH2

Apomorphine Injectable Solution

Other

used as a tool to induce nausea

Saline (0.9% NaCl)

Other

Placebo

Primary outcomes

  1. Change in GLP-1 induced nausea intensity

    Time frame: From enrollment to the end of treatment at up to 12 weeks.

    The primary endpoint is the change in GLP-1-induced nausea intensity, measured by a 0-100 mm visual analogue scale (VAS), between study visits, with and without GIP infusion.

Sponsors and collaborators

Lead sponsor

University of Copenhagen

Other

Registry information

Acronym: GIP EMESIS

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jul 7, 2026
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.